Amylyx reports positive safety data for AMX0114 in LUMINA trial
Amylyx Pharmaceuticals, Inc. presented positive safety data from the Phase 1 LUMINA trial of AMX0114 at the ENCALS Meeting 2026. Cohort 1 showed no drug-related serious adverse events, and biomarker levels remained near baseline. The trial is enrolling participants across four dose levels in Canada and the United States.
*this image is generated using AI for illustrative purposes only.
Amylyx Pharmaceuticals, Inc. presented positive safety data from its first-in-human, dose-ranging Phase 1 LUMINA trial of AMX0114 at the European Network to Cure ALS (ENCALS) Meeting 2026, held from June 24-26, 2026 in Madrid, Spain. The data showed no drug-related serious adverse events (SAEs) and no serious neurological adverse events (AEs) in Cohort 1, which evaluated the lowest dose level of 12.5 mg. These findings support the continued evaluation of AMX0114 at higher dose levels in the multiple ascending dose trial.
AMX0114 is an investigational antisense oligonucleotide (ASO) targeting calpain-2, a calcium-activated protease that drives axonal degeneration in ALS. The drug has received U.S. Food and Drug Administration (FDA) Fast Track designation. In preclinical studies, AMX0114 demonstrated potent, dose-dependent reduction in calpain-2 levels and improved neuronal survival.
The LUMINA trial (NCT06665165) is a multinational, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of AMX0114. The trial is enrolling approximately 48 adult participants across four dose levels. Participants are randomized 3:1 to receive AMX0114 or placebo via intrathecal administration once every four weeks for up to four doses. Study sites are active in Canada and the United States.
Biomarker levels, including spectrin breakdown product 145 (SBDP-145), neurofilament light (NfL), and phosphorylated neurofilament heavy (pNFH), remained near baseline in Cohort 1. These markers are key indicators of neuronal damage. The stability of these markers at the lowest dose level suggests potential neuroprotective effects, which will be further investigated in future cohorts.
Cohorts 1 (12.5 mg) and 2 (25 mg) are fully enrolled, and Cohort 3 (50 mg) is currently enrolling. The company anticipates a total of four dose levels in this dose-ranging study. The presentation at the ENCALS Meeting 2026 provides early insights into the safety and biomarker effects of AMX0114, setting the stage for further clinical development.
| Trial Component | Details |
|---|---|
| Trial Name | LUMINA |
| Phase | Phase 1 |
| Drug | AMX0114 |
| Lowest Dose Evaluated | 12.5 mg |
| Serious Adverse Events (SAEs) | None |
| Serious Neurological AEs | None |
| Key Biomarkers Monitored | SBDP-145, NfL, pNFH |
How might biomarker responses for SBDP-145, NfL, and pNFH change at higher dose levels (25 mg, 50 mg, and beyond), and what thresholds would Amylyx consider clinically meaningful?
Given AMX0114's intrathecal delivery mechanism, what competitive advantages or challenges does it face compared to other ALS therapies currently in development or on the market?
If higher dose cohorts continue to show a clean safety profile, what would Amylyx's likely timeline and regulatory strategy be for advancing AMX0114 into Phase 2 efficacy trials?
19
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
